These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 14613468)

  • 1. Examination of resource use and clinical interventions associated with chronic kidney disease in a managed care population.
    London R; Solis A; Goldberg GA; Wade S; Chan WW
    J Manag Care Pharm; 2003; 9(3):248-55. PubMed ID: 14613468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resource use and patient care associated with chronic kidney disease in a managed care setting.
    Robbins JD; Kim JJ; Zdon G; Chan WW; Jones J
    J Manag Care Pharm; 2003; 9(3):238-47. PubMed ID: 14613467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of secondary hyperparathyroidism on disease progression, healthcare resource utilization and costs in pre-dialysis CKD patients.
    Schumock GT; Andress D; E Marx S; Sterz R; Joyce AT; Kalantar-Zadeh K
    Curr Med Res Opin; 2008 Nov; 24(11):3037-48. PubMed ID: 18826748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organisations.
    Duh MS; Mody SH; McKenzie RS; Lefebvre P; Gosselin A; Bookhart BK; Piech CT
    Drugs Aging; 2006; 23(12):969-76. PubMed ID: 17154661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations.
    Duh MS; Mody SH; Scott McKenzie R; Lefebvre P; Gosselin A; Tak Piech C
    Clin Ther; 2006 Sep; 28(9):1443-50. PubMed ID: 17062316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of secondary hyperparathyroidism with CKD progression, health care costs and survival in diabetic predialysis CKD patients.
    Schumock GT; Andress DL; Marx SE; Sterz R; Joyce AT; Kalantar-Zadeh K
    Nephron Clin Pract; 2009; 113(1):c54-61. PubMed ID: 19590235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hospital-based inpatient resource utilization associated with autosomal dominant polycystic kidney disease in the US.
    Blanchette CM; Craver C; Belk KW; Lubeck DP; Rossetti S; Gutierrez B
    J Med Econ; 2015 Apr; 18(4):303-11. PubMed ID: 25372357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcomes and Economic Impact of Starting Hemodialysis with a Catheter after Predialysis Arteriovenous Fistula Creation.
    Al-Balas A; Shariff S; Lee T; Young C; Allon M
    Am J Nephrol; 2019; 50(3):221-227. PubMed ID: 31394548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of care for patients with chronic kidney disease in the United States: dying for improvement.
    Owen WF
    J Am Soc Nephrol; 2003 Jul; 14(7 Suppl 2):S76-80. PubMed ID: 12819307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidisciplinary predialysis programs: quantification and limitations of their impact on patient outcomes in two Canadian settings.
    Levin A; Lewis M; Mortiboy P; Faber S; Hare I; Porter EC; Mendelssohn DC
    Am J Kidney Dis; 1997 Apr; 29(4):533-40. PubMed ID: 9100041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims data.
    Margolis J; Barron JJ; Grochulski WD
    J Manag Care Pharm; 2005; 11(9):727-34. PubMed ID: 16300416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predialysis nephrology care and costs in elderly patients initiating dialysis.
    Stroupe KT; Fischer MJ; Kaufman JS; O'Hare AM; Sohn MW; Browning MM; Huo Z; Hynes DM
    Med Care; 2011 Mar; 49(3):248-56. PubMed ID: 21224743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An examination of productivity and resource utilization associated with epoetin alfa treatment in employees with predialysis chronic kidney disease.
    Papatheofanis F; Bookhart BK; Muser E; Piech CT
    J Occup Environ Med; 2008 May; 50(5):584-9. PubMed ID: 18469628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated therapies including erythropoietin decrease the incidence of dialysis: lessons from mapping the incidence of end-stage renal disease in Japan.
    Furumatsu Y; Nagasawa Y; Hamano T; Iwatani H; Iio K; Shoji T; Ito T; Tsubakihara Y; Imai E
    Nephrol Dial Transplant; 2008 Mar; 23(3):984-90. PubMed ID: 17956890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nephrotoxic Medication Exposure in U.S. Adults with Predialysis Chronic Kidney Disease: Health Services Utilization and Cost Outcomes.
    Davis-Ajami ML; Fink JC; Wu J
    J Manag Care Spec Pharm; 2016 Aug; 22(8):959-68. PubMed ID: 27459659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic kidney disease: the distribution of health care dollars.
    St Peter WL; Khan SS; Ebben JP; Pereira BJ; Collins AJ
    Kidney Int; 2004 Jul; 66(1):313-21. PubMed ID: 15200439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The economic impact of epoetin alfa therapy on delaying time to dialysis in elderly patients with chronic kidney disease.
    Lefebvre P; Duh MS; Mody SH; Bookhart B; Piech CT
    Dis Manag; 2007 Feb; 10(1):37-45. PubMed ID: 17309363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations with predialysis vascular access management.
    Lee T; Barker J; Allon M
    Am J Kidney Dis; 2004 Jun; 43(6):1008-13. PubMed ID: 15168380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective.
    Laliberté F; Bookhart BK; Vekeman F; Corral M; Duh MS; Bailey RA; Piech CT; Lefebvre P
    J Manag Care Pharm; 2009 May; 15(4):312-22. PubMed ID: 19422271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and Economic Impact of Hyperkalemia in Patients with Chronic Kidney Disease and Heart Failure.
    Polson M; Lord TC; Kangethe A; Speicher L; Farnum C; Brenner M; Oestreicher N; Alvarez P
    J Manag Care Spec Pharm; 2017 Apr; 23(4-a Suppl):S2-S9. PubMed ID: 28436256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.